Arbutus Biopharma Corporation ABUS Accounts Receivable
Accounts Receivable at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:AccountsAndOtherReceivablesNetCurrent.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's accounts receivable?
- Arbutus Biopharma Corporation (ABUS) reported accounts receivable of $178.74M in Q1 2026.
- How has Arbutus Biopharma Corporation's accounts receivable changed year-over-year?
- Arbutus Biopharma Corporation's accounts receivable increased by 15021.9% year-over-year, from $1.18M to $178.74M.
- What is the long-term trend for Arbutus Biopharma Corporation's accounts receivable?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's accounts receivable has grown at a -100.0% compound annual growth rate (CAGR), from $1.31M to $0.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.